PuSH - Publication Server of Helmholtz Zentrum München: Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Stemmer, K. ; Finan, B.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Müller, T.D.

Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

Adv. Drug Deliv. Rev. 159, 34-53 (2020)

Postprint

DOI

	Open Access Green

Abstract
Metrics
Extra information

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Review

Corresponding Author

Keywords Diabetes ; Dyslipidemia ; Incretins ; Lipoproteins ; Obesity; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Dependent Insulinotropic Polypeptide; Lipoprotein-lipase Activity; Low-density-lipoprotein; Dipeptidyl Peptidase-4 Inhibitor; Impaired Glucose-tolerance; Brown Adipose-tissue; High-fat; Receptor Agonist

ISSN (print) / ISBN 0169-409X

e-ISSN 1872-8294

Journal Advanced Drug Delivery Reviews

Quellenangaben Volume: 159, Pages: 34-53

Publisher Elsevier

Publishing Place Amsterdam

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Diabetes and Obesity (IDO)

Grants German Center for Diabetes Research (DZD e.V.)
Helmholtz Alliance ICEMED
Helmholtz Initiative on Personalized Medicine iMed by Helmholtz Association
Helmholtz cross-program topic "Metabolic Dysfunction"
German Research Foundation Grants
European Research Council ERC AdG HypoFlam
Alexander von Humboldt Foundation